The discovery and clinical evolution of 5-HT re-uptake inhibiting drugs are reviewed. From the widespread distribution of 5-HT in bodily systems and the range of effects and side effects reported, it is concluded that these and other drugs active on the 5-HT system are likely to have beneficial effects on a range of other physical conditions coincident and co-morbid with the affective disorders. Clinical vigilance may therefore be repaid with serendipitous discoveries.
Adams C., Essali M.A. (1991) Working with clozapine. Psychiatr Bull15: 336-338
2.
Axelrod J. (1972) Biogenic amines and their impact on psychiatry . Semin Psychiatr4: 199-210
3.
Axelrod J., Inscoe J.K. (1963) The uptake and binding of circulating serotonin and the effect of drugs. J Pharmacol Exp Ther141: 161-169
4.
Axelrod J., Whitby R., Hertting G. (1961) Effect of psychotropic drugs on the uptake of [3H] noradrenaline by tissues. Science133: 383-384
5.
Baldwin D., Fineberg N., Montgomery S. (1991) Fluoxetine, fluvoxamine and extrapyramidal disorders . Int Clin Psychopharmacol6: 51-58
6.
Beaumont G. (1977) Sexual side effects of clomipramine. J Internal Med Res5 (Suppl 1): 37-44
7.
Bunney WE, Davis J.M. (1965) Norepinephrine in depressive reactions. Arch Gen Psychiatr13: 483-494
8.
Carlsson A. (1990a) The rise of psychopharmacology and early modern brain research. J Psychopharmacol4: 120-126
9.
Carlsson A. (1990b) Discussion. J Psychopharmacol4: 168-170
10.
Creaney W., Murray I., Healy D. (1991) Antidepressant induced suicidal ideation. Hum Psychopharmacol6: 329-332
11.
Guilleminault C., Raynal D., Takahashi S., Carskadon M., Dement W. (1976) Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand54: 71-87
12.
Halman M., Goldbloom D.S. (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatr28: 518-521
13.
Healy D. (1987) The structure of psychopharmacological revolutions . Psychiatr Dev4: 349-376
14.
Healy D. (1990) The psychopharmacological era; notes toward a history . J Psychopharmacol4: 152-167Healy D. (1991a). The marketing of 5-HT; depression or anxiety? Br J Psychiatr158: 737-742
15.
Healy D. (1991b) What do 5HT-reuptake inhibitors do in obsessive-compulsive disorder. Hum Psychopharmacol6: 325-328
16.
Healy D. (1993) Psychiatric drugs explained. Wolfe Medical Publications (in press)
17.
Kandel E.R., Klein M., Castellucci V.F., Schacher S., Goelet P. (1986) Some principles emerging from the study of short and long-term memory. Neurosci Res3: 498-520
18.
Kerr J.S., Sherwood N., Hindmarch I. (1991) The comparative psychopharmacology of 5HT reuptake inhibitors. Hum Psychopharmacol6: 313-318
19.
Leonard B.E. (1992) Sub-types of serotonin receptor: biochemical changes and pharmacological consequences. Int Clin Psychopharmacol7: 13-21
20.
Lipinski J.F., Mallya G., Zimmerman P., Pope H.G. (1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatr50: 339-342
21.
Lucey JV, Butcher G., Clare A.W., Dinan T.G. (1992) Buspirone-induced prolactin responses in obsessive-compulsive disorder (OCD): is OCD a 5HT-2 receptor disorder. Hum Psychopharmacol7: 45-50
22.
Mann C C M, Plummer M L P (1991) The aspirin wars: money medicine and one hundred years of rampant competition. Alfred Knopf, New York.
23.
Marshall E.F., Stirling G.S., Tait A.C., Todrick A. (1960) The effect of iproniazid and imipramine on the blood platelet 5-hydroxytryptamine level in man. Br J Pharmacol15: 35-41
24.
McEntee W.J., Crook T.H. (1991) Serotonin, memory and the aging brain. Psychopharmacology103: 143-149
25.
Meltzer H.Y., Young M., Metz J., Fang V.S., Schyve P.M., Arora R.C. (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm45: 165-175
26.
Modell J.G. (1989) Repeated observations of yawning, clitoral engorgement and orgasm associated with fluoxetine administration. J Clin Psychopharmacol9: 63-65
27.
Passouant P., Cadhillac J., Billiard M., Besset A. (1973) La suppression du sommeil paradoxal par la clomipramine . Therapie28: 379-392
28.
Pletscher A., Bernstein A. (1958) Increase of 5-hydroxytryptamine in blood platelets by isopropyl-isonicotinic acid hydrazide. Nature181: 1133
29.
Rapoport M.M. (1949) Serum vasoconstrictor (serotonin). Presence of creatinine in the complex. A proposed structure of the vasoconstrictor. J Biol Chem180: 961-969
30.
Rapoport M.M., Green A.A., Page I.H. (1947) Purification of the substance which is responsible for vasoconstrictor activity of serum. Fed Proc6: 184
31.
Riley A.J., Goodman R.E., Kellet J.M., Orr R. ( 1989) Double blind trial of yohimbine in the treatment of erection inadequacy. Sexual Marital Ther4: 17-26
32.
Rothschild A.J., Locke C.A. (1991) Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatr52: 491-493
33.
Segraves R.T. (1989) Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatr46: 275-284
34.
Schildkraut J.J. (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatr122: 509-522
35.
Sullivan G., Lukoff D. (1990) Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatr41: 1238-1241
36.
Teicher M.H., Glod C., Cole J.O. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatr147: 207-210
37.
Todrick A. (1991) Imipramine and 5-HT re-uptake inhibition. J Psychopharmacol5: 263-267
38.
Tricklebank M.D. (1989) Interactions between dopamine and 5HT-3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci10: 127-129
39.
Twarog B.M., Page I.H. (1953) Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol175: 157-161
40.
Vialli M., Erpsamer V. (1933) Cellule enterocromaffini e cellule basigranulose acidofile nei vertebrati. Zischr Zellforsch U. Mikr Anat19: 743
Wilson C.A. (1992) 5-hydroxytryptamine (5HT) and sexual behaviour . J Psychopharmacol Abstract A-1, British Association for Psychopharmacology AGM, Cambridge1992
